## **SCOLIOSIS SUPPORT AND RESEARCH** # **ANNUAL REPORT & ACCOUNTS 31ST MARCH 2025** **Registered Charity Number 1181463** ## **EDMUND CARR LLP** Chartered Accountants 146 New London Road Chelmsford Essex CM2 0AW ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **YEAR ENDED 31 MARCH 2025** **----- Start of picture text -----**
CONTENTS
Reference & Admin Details 1
Report of the Trustees 2
Independent examiner's report 5
Statement of Financial Activities (incorporating the income 6
and expenditure account)
Balance Sheet 7
Cashflow Statement 8
Notes to the financial statements 10
**----- End of picture text -----**
## **SCOLIOSIS SUPPORT AND RESEARCH** ## **REFERENCE AND ADMINISTRATIVE DETAILS** ## **YEAR ENDED 31 MARCH 2025** **----- Start of picture text -----**
Registered Charity Name Scoliosis Support and Research
formerly Scoliosis Association UK (SAUK)
Charity Number 1181463
Registered Office Ground Floor
329 Latimer Road
London
W10 6RA
Trustees Mr I Nelson (Chair)
Mrs H Gale (Appointed December 2024)
Dr N Jones
Mr J Leong
Mr C Nnadi
Dr M Noordeen
Mr T Tsirikos (Resigned December 2024)
Ms R Weil
Mr J Zorab
Patron HRH Princess Eugenie
Chief Executive Lesley McGinty
Independent Examiner Alex Stone FCCA
Edmund Carr LLP
Chartered Accountants
146 New London Road
Chelmsford
Essex
CM2 0AW
Bankers CAF Bank
25 Kings Hill Avenue
Kings Hill
West Malling
Kent
ME19 4JQ
**----- End of picture text -----**
1 ## **SCOLIOSIS SUPPORT AND RESEARCH TRUSTEES' ANNUAL REPORT** ## **YEAR ENDED 31 MARCH 2025** The Trustees have pleasure in presenting their report and the unaudited financial statements of the charity for the year ended 31 March 2025. ## **Annual Report from the Chair, 2024-25** Having legally completed the merger of Scoliosis Association UK and British Scoliosis Research Foundation (BSRF) in January 2023, January 2024 saw the official launch of our new name, Scoliosis Support and Research, with associated rebranding to reflect our ethos and “personality”. This relaunch was very well received, with very positive feedback. We completely rebuilt the website with much more information. This is still very much work in progress, with new functionality being added. The objects of the charity, revised post merger are, for the public benefit, to preserve and protect the physical and mental health of persons with the spinal condition known as scoliosis and other spinal conditions, particularly but not exclusively by: (i) providing advice, support and information to people affected by scoliosis and other spinal conditions, their families and friends; (ii) raising awareness of scoliosis and other spinal conditions among health professionals and the general public; (iii) making available to patients and their families and friends the experience of others with scoliosis and other spinal conditions; (iv) raising awareness about the prevalence and effects of scoliosis and other spinal conditions; (v) promoting research into scoliosis and other spinal conditions and more particularly into their causes and into the chest and heart consequences thereof; (vi) holding the international Philip Zorab Symposium, a unique international scoliosis meeting, at a frequency to be determined by the trustees and the Zorab Committee chair. We continue to support those affected by scoliosis through our Helpline – by telephone and email – as well as providing online counselling groups and a “safe space” on our Facebook group. We have expanded the scope of our community (membership) to enable more people to access our Hill Pedder Minns Welfare fund and twice yearly Backbone Magazine. During this year, we started organising Patient Events again. We organise events of up to 100 people in locations across the UK to discuss the issues faced by families and individuals affected by scoliosis. These provide the opportunity to hear from scoliosis specialists and treatment experts, and get answers to your questions. They are also a great opportunity for people to meet each other and share stories and information about their experiences with scoliosis. We support research by collaborating with researchers and making our members aware of the research and inviting them to participate. We have continued to offer the Charles Manning Award, which was a BSRF award arising from a legacy by Mr. Charles Manning, FRCS, to help early career researchers attend conferences to present their work. We awarded a total of £1,150 this financial year. Our patient events and greater social media presence have offered far more opportunity for patients to become involved with research, as specified in our Priority Setting Partnership. 2 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **TRUSTEES' ANNUAL REPORT** _**(continued)**_ ## **YEAR ENDED 31 MARCH 2025** The internationally renowned Zorab Symposium, which was historically organised by BSRF, was held on 19 and 20 June 2025. ## **Structure, governance, and management** Scoliosis Support and Research (SSR) - formerly Scoliosis Association UK - was incorporated on January 7th, 2019, as a charitable incorporated organisation (CIO). The CIO is entered in the Central Register of Charities by the Charity Commissioners for England and Wales with registration number 1181463. SSR is governed by a board of Trustees, consisting of a combination of spinal surgeons, general practitioners, scientists, and lay members. The office staff is composed of a Chief Executive, supported by a Community Engagement Manager and a Fundraising and Communications Manager. The Board of Trustees meets four times a year and the Chief Executive reports formally to the Board at these meetings. New Trustees are generally selected from contacts with knowledge of scoliosis and related issues. Following a Strategy day in October 2024 we have plans to diversify trustee expertise through subsequent replacements. The Trustees confirm that they have had due regard to guidance published by the Charity Commission on public benefit. SSR’s aims are wholly directed at delivering public benefit. The trustees have considered the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate these risks. Key areas of focus include, financial sustainability, data protection, and reputational risk. The trustees recognise the importance of risk management and are in the process of developing a formal risk register. Key risks are discussed regularly at board meetings and mitigation strategies are considered as part of ongoing governance. During the reporting period, there were no related party transactions. No trustee or member of staff received any remuneration or reimbursement for services provided to the charity, nor did any have a financial interest in any contract or grant provided by the charity. The Trustees of SSR are listed on page 1. HRH Princess Eugenie is SSR’s Royal Patron Dr Stephanie Clark, PhD, co-founder of Scoliosis Association UK was appointed as a Patron on standing down from the Board back in December 2023. The staff team during 2024 -25 consisted of Mrs Lesley McGinty, who has been in post as Chief Executive since April 2021; Ellie Wilson, Fundraising and Communications Officer, November 2023 to December 2024; James Alculmbre as Community Engagement Manager from June 2024 and Will Thommes who rejoined us as Fundraising and Communications Manager in January 2025. All employees are based at SSR’s premises at Ground Floor 329 Latimer Road, London W10 6RA. 3 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **TRUSTEES' ANNUAL REPORT** _**(continued)**_ ## **YEAR ENDED 31 MARCH 2025** ## **Finance** Unrestricted income, made up of donations, legacies, and fundraised income including Gift Aid was £325,631 compared with £202,176 in the previous year. Notably, Community Fundraising increased from £62,143 to £108,824 thanks in no small part to a large, very engaged Marathon team. Our membership subscriptions stayed much the same as in the previous year. We spent £302,756 in the current year compared with £277,359 in the previous year largely due to the costs of the rebrand, a fundraising consultant and legal fees for a research agreement. Legacies brought in £120,231 with notification of a significant legacy (over £200k) to be received in the next financial year. We are developing new projects and ways to support people with scoliosis, with the benefit of the increased funds. During the year we paid out a total of £43,986 in respect of research grants awarded in the current and prior years; £10,269 in respect of support grants, defrayed by a very generous donation of £3,000, and as mentioned above, £1,150 for research travel grants via the Charles Manning Award. We received continued support from the Sir James Reckitt Charity (support) and the Robert Luff Foundation (research). SSR had total funds at the year end of £1,261,146 of which £617,922 were unrestricted, £469,808 designated and £173,416 restricted. Our reserves policy is to maintain a minimum of £100,000 of unrestricted funds. Our unrestricted funds were significantly higher than this at the year end due to the transfer of assets at point of merger and the receipt of a significant legacy in 2023. Funds will be used to scope and sponsor a research project of £100,000 plus, and further develop patient support though regional meetings and talking therapy support. It was agreed by the Board that £1million was to be invested and after the required due diligence and security was undertaken, this was completed in July 2024, with our investment being managed by Rathbones. The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporing by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16 July 2014. This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies’ exemption. Approved by the Trustees on 3 November 2025 and signed on their behalf by: ........................................ **Ian Nelson Chair of the Trustees** 4 ## **SCOLIOSIS SUPPORT AND RESEARCH INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES** ## **YEAR ENDED 31 MARCH 2025** I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 March 2025 which are set out on pages 6 to 16. ## **Responsibilities and basis of report** As the charity’s trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (‘the Act’). I report in respect of my examination of the charity’s accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act. ## **Independent examiner's statement** Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Certified Accountants, which is one of the listed bodies. I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. accounting records were not kept in respect of the charity as required by section 130 of the Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a ‘true and fair view’ which is not a matter considered as part of an independent examination. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. ................................... ## **Alex Stone FCCA** Edmund Carr LLP 146 New London Road Chelmsford CM2 0AW 3 November 2025 5 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **STATEMENT OF FINANCIAL ACTIVITIES** ## **YEAR ENDED 31 MARCH 2025** |**Note**
**Income from:**
Donations and legacies
**2**
Other trading activities
**3**
Investments
**4**
Charitable activities
**5**
**Total Income**
**Expenditure on:**
Raising funds
Charitable activities
**6**
**Total Expenditure**
Net income/(expenditure)
Net gains/(losses) on investments
**10**
Transfers between funds
**Net Movement in Funds**
**Reconciliation of Funds**
Total funds brought forward
**Total Funds Carried Forward**|**Unrestricted**
**Funds**
**2025**
**£**
288,587
2,627
21,480
12,937
325,631
8,022
293,584
301,606
24,025
(32,850)
-
(8,825)
1,096,555
£1,087,730|**Restricted**
**Funds**
**2025**
**£**
25,000
-
-
-
25,000
-
1,150
1,150
23,850
-
-
23,850
149,566
£173,416|**Total**
**Funds**
**2025**
**£**
313,587
2,627
21,480
12,937
350,631
8,022
294,734
302,756
47,875
(32,850)
-
15,025
1,246,121
£1,261,146|**Total**
**Funds**
**2024**
**£**
265,579
1,571
23,545
15,095
305,790
7,386
269,973
277,359
28,431
-
-
28,431
1,217,690
£1,246,121| |---|---|---|---|---| All of the above amounts relate to continuing activities. The notes on pages 9 to 16 form part of these financial statements. 6 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **BALANCE SHEET** ## **AS AT 31 MARCH 2025** |**Note**
**Fixed Assets**
Tangible fixed assets
**10**
Investments
**11**
**Current Assets**
Debtors
**12**
Cash at bank and in hand
**Creditors: Amounts falling**
**due within one year**
**13**
**Net Current Assets**
**Net Assets**
**The funds of the charity:**
Unrestricted Funds
**15**
Designated Funds
Total Unrestricted Funds
Restricted Funds
**16**
**Total Charity Funds**|**£**
**£**
444
1,117,160
1,117,604
37,934
174,370
212,304
(68,762)
143,542
1,261,146
617,922
469,808
1,087,730
173,416
1,261,146
**2025**|**£**
**£**
888
-
888
66,480
1,255,791
1,322,271
(77,038)
1,245,233
1,246,121
610,678
485,877
1,096,555
149,566
1,246,121
**2024**| |---|---|---| These financial statements were approved by the Trustees on 3 November 2025 and are signed on their behalf by: …................................................ ## **IAN NELSON (CHAIR OF THE TRUSTEES)** The notes on pages 9 to 16 form part of these financial statements. 7 ## **SCOLIOSIS SUPPORT AND RESEARCH CASHFLOW STATEMENT** ## **YEAR ENDED 31 MARCH 2025** |**Note**
**Cash flows from operating activities:**
Net movement in funds
_Adjustments for:_
Depreciation charges
**10**
Revaluation of Investment
**11**
Investment income
**4**
Decrease / (increase) in debtors
**12**
Increase / (decrease) in creditors
**14**
**Cash provided by / (used in)**
**operating activities**
**Cash flows from investing activities:**
Investment income
**4**
Purchase of Investment
**11**
**Cash provided by investing activities**
Increase / (decrease) in cash and cash
equivalents in the year
Cash and cash equivalents at start of
year
**Cash and cash equivalents at end of**
**year**|**2025**
15,025
444
32,850
(21,480)
28,546
(8,276)
47,109
21,480
(1,150,010)
(1,128,530)
(1,081,421)
1,255,791
174,370|**2024**
28,431
444
-
(23,545)
(60,943)
(74,784)
(130,397)
23,545
-
23,545
(106,852)
1,362,643
1,255,791| |---|---|---| **The notes on pages 9 to 16 form part of these financial statements.** 8 ## **SCOLIOSIS SUPPORT AND RESEARCH NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 31 MARCH 2025** ## **1) ACCOUNTING POLICIES** ## **General information and basis of preparation** Scoliosis Support and Research is a Charitable Incorporated Organisation, registered in England and Wales (charity no: 1181463). The charity constitutes a public benefit entity as defined by FRS102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) issued in October 2019, the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Charities Act 2011 and UK Generally Accepted Accounting Practice. The financial statements have been prepared to give a ‘true and fair’ view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a ‘true and fair view’. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn. The financial statements are prepared on a going concern basis under the historical cost convention modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charity and rounded to the nearest £1. The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated. ## **Income recognition** All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income can be measured reliably. ## **Expenditure recognition** All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to the category. Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them. Governance costs are those incurred in connection with the administration of the charity and compliance with consitutional and statutory requirements. Irrecoverable VAT is charged as an expense against the activity for which the expenditure arose. 9 ## **SCOLIOSIS SUPPORT AND RESEARCH NOTES TO THE FINANCIAL STATEMENTS** ## **YEAR ENDED 31 MARCH 2025** ## **1) ACCOUNTING POLICIES (continued)** ## **Taxation** The charity is exempt from taxation in respect of income or capital gains to the extent that such income or gains are applied exclusively to charitable purposes. ## **Fixed assets** The charity's policy is to capitalise fixed assets over £1,000. Expenditure below this threshold is recognised as expenditure in the year in which it occurs. ## **Depreciation** Depreciation is provided on tangible fixed assets so as to write off the cost or valuation, less any estimated residual value, over their expected useful economic life as follows: **Asset class Depreciation method and rate** Equipment 25% straight line ## **Investments** Investments are stated at market value. Realised gains and losses on disposals and unrealised gains or losses when the investments are revalued at the period end are reflected in the Statement of Financial Activities. ## **Stocks** No value is placed on stocks of stationery or advertising materials held by the charity. ## **Debtors and creditors receivable /payable within one year** Debtors and creditors receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure. ## **Cash and cash equivalents** Cash and cash equivalents comprise cash on hand and at bank. ## **Fund Accounting** Funds held by the charity are either: Unrestricted general funds - these are funds that can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds - these are funds that can only be used for particular restricted purposes within the objects of the charity. Designated funds - these are funds that have been set aside by the trustees for particular purposes. 10 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MARCH 2025** ## **2) DONATIONS & LEGACIES** |Donations
Legacies
Gift aid
Grants|**Unrestricted**
**funds**
**£**
158,413
120,231
6,943
3,000
288,587|**Restricted**
**funds**
**£**
-
-
-
25,000
25,000|**Total funds**
**2025**
**£**
158,413
120,231
6,943
28,000
313,587|**Total funds**
**2024**
**£**
109,686
42,887
6,392
106,614
265,579| |---|---|---|---|---| Legacies notified to the charity during the year which did not meet income recognition criteria at the year end have an estimated value of £275,000 (2024 - nil). ## **3) OTHER TRADING ACTIVITIES** |**Unrestricted**
**funds**
**Restricted**
**funds**
**£**
**£**
Website sales
2,627
-
**4) INVESTMENTS**
**Unrestricted**
**funds**
**Restricted**
**funds**
**£**
**£**
Bank interest receivable
10,565
-
Investment Income
10,915
-
21,480
-
**5) INCOME FROM CHARITABLE ACTIVITIES**
**Unrestricted**
**funds**
**Restricted**
**funds**
**£**
**£**
Subscriptions
12,937
-|**Total funds**
**2025**
**£**
2,627
**Total funds**
**2025**
**£**
10,565
10,915
21,480
**Total funds**
**2025**
**£**
12,937|**Total funds**
**2024**
**£**
1,571
**Total funds**
**2024**
**£**
23,545
23,545
**Total funds**
**2024**
**£**
15,095| |---|---|---| 11 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MARCH 2025** ## **6) EXPENDITURE ON CHARITABLE ACTIVITIES** |Awards
Provision of Therapy
Research Grants
Events
Staff costs
Website and magazine costs
Support costs (Note 7)
Governance costs (Note 8)
**7)**
**SUPPORT COSTS**
Office costs
Meetings, travel & subsistence
Bank Charges
**8)**
**GOVERNANCE COSTS**
Fees payable to independent examiner
Other professional fees|**Unrestricted**
**funds**
**£**
6,069
4,200
10,000
12,822
136,176
18,135
98,522
7,660
293,584
**Unrestricted**
**funds**
**£**
90,251
3,938
4,333
98,522
**Unrestricted**
**funds**
**£**
4,500
3,160
7,660|**Restricted**
**funds**
**£**
1,150
-
-
-
-
-
-
-
1,150
**Restricted**
**funds**
**£**
-
-
-
-
**Restricted**
**funds**
**£**
-
-
-|**Total funds**
**2025**
**£**
7,219
4,200
10,000
12,822
136,176
18,135
98,522
7,660
294,734
**Total funds**
**2025**
**£**
90,251
3,938
4,333
98,522
**Total funds**
**2025**
**£**
4,500
3,160
7,660|**Total funds**
**2024**
**£**
4,539
-
3,462
3,643
154,126
14,485
64,418
25,300
269,973
**Total funds**
**2024**
**£**
59,587
2,221
2,610
64,418
**Total funds**
**2024**
**£**
5,100
20,200
25,300| |---|---|---|---|---| ## **9) STAFF COSTS AND EMOLUMENTS** |Salaries and wages
Social security costs
Employer pension costs|**2025**
**£**
125,417
8,751
2,008
136,176|**2024**
**£**
143,717
8,389
2,020
154,126| |---|---|---| Average number of paid staff on a head count basis for the year was 3 (2024 - 7) Remuneration benefits of key management personnel of the charity total £67,492 (2024: £60,518). 12 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 31 MARCH 2025** ## **10) TANGIBLE FIXED ASSETS** |**COST**
As at 1 April 2024
Additions
**At 31 March 2025**
**DEPRECIATION**
As at 1 April 2024
Charge for the period
**At 31 March 2024**
**NET BOOK VALUE**
**At 31 March 2025**
At 31 March 2024
**11)**
**INVESTMENTS**
Market value as at 1 April 2024
Additions at cost
Net loss on revaluation
Market value as at 31 March 2025|**Equipment**
**£**
1,776
-
1,776
888
444
1,332
444
888
**2025**
**£**
-
1,150,010
(32,850)
1,117,160|**Total**
**£**
1,776
-
1,776
888
444
1,332
444
888
**2024**
**£**
-
-
-
-| |---|---|---| All investments are managed by Rathbones Investment Management. |**12)**
**DEBTORS**
Other debtors
Prepayments and accrued income|**2025**
**£**
6,800
31,134
37,934|**2024**
**£**
6,800
59,680
66,480| |---|---|---| 13 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **NOTES TO THE FINANCIAL STATEMENTS (continued)** ## **YEAR ENDED 31 MARCH 2025** ## **13) CREDITORS: Amounts falling due within one year** |Creditors
Research Grants Payable
Accruals|**2025**
**£**
4,772
59,704
4,286
68,762|**2024**
**£**
4,292
69,136
3,610
77,038| |---|---|---| ## **14) COMMITMENTS UNDER OPERATING LEASES** Total rental payments due under operating leases are as follows: |Within 1 year
Within 2 to 5 years
**5)**
**UNRESTRICTED FUNDS**
**Balance at**
**1 Apr 2024**
**£**
General funds
610,678
_Designated funds:_
a)
Ailee Harrison Fund
4,675
b)
Hill, Pedder, Minns Fund
28,226
c) BSRF funds
452,976
d)
Counselling Support
-
1,096,555|**Income**
**£**
322,631
-
-
-
3,000
325,631|**Expenditure**
**£**
(282,537)
(350)
(5,719)
(10,000)
(3,000)
(301,606)|**2025**
**£**
4,121
-
4,121
**Gains/**
**(losses)**
**£**
(32,850)
-
-
-
-
(32,850)|**2024**
**£**
24,727
4,121
28,848
**Balance at**
**31 Mar**
**2025**
**£**
617,922
-
4,325
22,507
442,976
-
1,087,730| |---|---|---|---|---| ## **15) UNRESTRICTED FUNDS** a) The Ailee Harrison Fund arose from a legacy and is used to provide financial prizes for art projects. b) The Hill, Pedder, Minns Fund arose from 3 legacies and is used to provide grants to members of up to £500 for equipment relating to their condition. c) Funds transferred from BSRF have been designated for research purposes by the Trustees. d) Donations to aid with counselling support. 14 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **NOTES TO THE FINANCIAL STATEMENTS (continued)** ## **YEAR ENDED 31 MARCH 2025** ## **16) RESTRICTED FUNDS** |a)
ARISE
b)
BEIS fund (BSRF)
c)
Research funds|**Balance at**
**1 Apr 2024**
**Income**
**£**
**£**
15,098
-
30,854
-
103,614
25,000
149,566
25,000|**Expenditure**
**Investment**
**gains/ (losses)**
**Balance at**
**31 Mar 2025**
**£**
**£**
**£**
(1,150)
-
13,948
-
-
30,854
-
-
128,614
(1,150)
-
173,416| |---|---|---| a) ARISE fund provides travel grants of up to £500 to young researchers (the Charles Manning Award). b) Funds awarded by the BEIS 'Early Career Researchers Fund' to BSRF towards research projects supported by the charity were transferred to SSR following the merger. c) Grants received from Robert Luff Foundation and the Medical Research Council to fund research projects. |**Current Year**
**Unrestricted funds**
General
Designated funds
Restricted funds
**Total funds**
**Prior year**
**Unrestricted funds**
General
Designated funds
Restricted funds
**Total funds**|**Fixed assets**
**Net current**
**assets**
**Total**
**£**
**£**
**£**
474,380
143,542
617,922
469,808
-
469,808
173,416
-
173,416
1,117,604
143,542
1,261,146
**Fixed assets**
**Net current**
**assets**
**Total**
**£**
**£**
**£**
888
609,790
610,678
-
485,877
485,877
-
149,566
149,566
888
1,245,233
1,246,121| |---|---| ## **18) RELATED PARTY TRANSACTIONS** There were no related party transactions during the year (2024 - nil). Trustees do not receive any remuneration or fees. One trustee was reimbursed for expenses totalling £325 in respect of travel and subsistence (2024 - 3 trustees were reimbursed £1,037). 15 ## **SCOLIOSIS SUPPORT AND RESEARCH** ## **NOTES TO THE FINANCIAL STATEMENTS (continued)** ## **YEAR ENDED 31 MARCH 2025** ## **19) UNRESTRICTED FUNDS - PRIOR YEAR** |General funds
_Designated funds:_
a)
Ailee Harrison Fund
b)
Hill, Pedder, Minns Fund
c)
BSRF funds|**Balance at 1**
**Apr 2023**
**£**
671,990
4,675
31,865
462,308
1,170,838|**Income**
**£**
202,176
-
-
-
202,176|**Expenditure**
**Balance at**
**31 Mar 2024**
**£**
**£**
(263,488)
610,678
(3,639)
1,036
(9,332)
22,533
-
462,308
(276,459)
1,096,555| |---|---|---|---| a) The Ailee Harrison Fund arose from a legacy and is used to provide financial prizes for art projects. b) The Hill, Pedder, Minns Fund arose from 3 legacies and is used to provide grants to members of up to £500 for equipment relating to their condition. - c) Funds transferred from BSRF have been designated for research purposes by the Trustees. ## **20) RESTRICTED FUNDS - PRIOR YEAR** |a)
ARISE
b)
BEIS fund (BSRF)
c)
Research Funds|**Balance at 1**
**Apr 2023**
**Income**
**Expenditure**
**Balance at**
**31 Mar 2024**
**£**
**£**
**£**
**£**
15,998
-
(900)
15,098
30,854
-
30,854
-
103,614
-
103,614
46,852
103,614
(900)
149,566| |---|---| - a) ARISE fund provides travel grants of up to £500 to young researchers (the Charles Manning Award). - b) Funds awarded by the BEIS 'Early Career Researchers Fund' to BSRF towards research projects supported by the charity were transferred to SSR following the merger. - c) Grants received from Robert Luff Foundation and the Medical Research Council to fund research projects. 15